LOVE — Cannara Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- CA$168.91m
- CA$196.14m
- CA$107.32m
- 87
- 85
- 83
- 98
Annual cashflow statement for Cannara Biotech, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | C2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.53 | 2.31 | 6.95 | 6.44 | 13.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.229 | -0.822 | -0.337 | 0.39 | 6.56 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.82 | -11.5 | -5.64 | -2.5 | -6.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -2.09 | -6.08 | 5.91 | 10.7 | 20 |
| Capital Expenditures | -30.6 | -15.1 | -9.31 | -7.07 | -4.93 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.223 | -0.25 | -0.166 | 1.88 | -1.02 |
| Sale of Fixed Assets | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -30.8 | -15.3 | -9.48 | -5.19 | -5.95 |
| Financing Cash Flow Items | -1.49 | -1.61 | -4.63 | -3.9 | -3.74 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 33.3 | 25.5 | -4.19 | -3.14 | -6.32 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.388 | 3.96 | -7.84 | 2.35 | 7.74 |